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ttp://dx.doi.org/10.1016/j.jmoldx.2013.02.005The simplemethod for amplifying RNA targets (SMART) was used to detect K103N, a commonHIV-1 reverse
transcriptase drug-resistance mutation. Novel ampliﬁable SMART probes served as reporter molecules for
RNA sequences that are captured and separated on a microﬂuidic platform under zero-ﬂow conditions.
Assays were performed both off chip and in a microchip reservoir using a modiﬁed version of real-time
nucleic acid sequence-based ampliﬁcation, without the noncyclic phase, and 65C preheat. A total of 6000
copies/mL of the synthetic sequences were detected within 180 minutes of ampliﬁcation. Although the
sensitivity of research platforms is higher, SMART has the potential to offer comparable sensitivity and
speed to commercially available viral load and HIV detection kits. Furthermore, SMART uses an inexpen-
sive, practical, and more accurate isothermal exponential ampliﬁcation technique. The use of molecular
beacons resulted in relatively fast real-time detection (<180 minutes); however, they were also shown to
hinder the ampliﬁcation process when compared with end point detection. Finally, SMART probes were
used for modeling of K103N concentrations within an unknown sample. Only 1% of the SMART probes was
detected within the wild-type population (6 108 copies/mL). These results establish the groundwork for
point-of-care drug resistance and viral load monitoring in clinical samples, which can revolutionize HIV
patient care globally. (J Mol Diagn 2013, 15: 401e412; http://dx.doi.org/10.1016/j.jmoldx.2013.02.005)Supported by NIH grants 1R21 A1073808-01 A1, P30AI042853, and
R01AI066922.HIV is a daunting global pandemic.1 The development of
resistance to antiretroviral medications is the main cause for
treatment failure of HIV-infected individuals.2 K103N,
a point mutation of lysine to asparagine at position 103 of
the HIV reverse transcriptase (RT), is a common mutation
that causes high-level resistance to ﬁrst-generation non-
nucleoside reverse transcriptase inhibitors, such as nevir-
apine and efavirenz.3 HIV-infected patients receiving
nonnucleoside reverse transcriptase inhibitorebased treat-
ment who harbor K103N, either before or after exposure to
antiretroviral therapy, will most likely fail therapy and will
require alternative antiretroviral treatment.3 Therefore, the
detection of K103N, and other drug-resistance mutations, is
of great importance, especially in resource-limited settings
(RLSs), in which nonnucleoside reverse transcriptase
inhibitorebased regimens serve as ﬁrst-line treatment and
subsequent options are limited.4stigative Pathology
.A sensitive method to detect drug resistance in a small
rural clinic with no advanced laboratory infrastructure or the
use of a ﬁeld-deployable device to quickly detect resistance,
although extremely beneﬁcial, is lacking. The success of
any ﬁeld-deployable device will depend on variables such as
the cost per test, the need for specialized equipment, staff
expertise, refrigeration of reagents during shipping, and
shelf life. It would be beneﬁcial if the device would also use
minimal sample volume and provide excellent assay sensi-
tivity. Presently available assays, some with signiﬁcant
strengths, do not meet all these considerations.5,6
Various ﬁeld-deployable assays to detect HIV and/or
measure its RNA levels [viral load (VL)] are under devel-
opment,7 although, to our knowledge, none incorporate
Morabito et aldrug-resistance testing. For example, progress has been
made on a device for HIV detection via immunoassay
intended for RLS,8 and a successful antibody-based HIV-1/
2 test device has recently been granted Food and Drug
Administration approval for at-home use.9 Many commer-
cial HIV-1 detections and VL kits are available, including
the COBAS TaqMan assay (Roche, Pleasanton, CA), a real-
time HIV-1 assay (Abbott, Chicago, IL), and an Ultrasen-
sitive p24 Assay (PerkinElmer, Waltham, MA).10 These kits
use a variety of blood markers for detection and directly
monitor VL by measuring HIV-1 RNA or indirectly by
measuring p24 antigen, HIV antibodies, or CD4þ T-cell
counts. However, none of these HIV detection devices and/
or VL kits is capable of testing for drug-resistant mutations.
Two main commercial HIV genotyping assays are
available to monitor drug resistance, ViroSeq (Abbott) and
TRUGENE (Siemens, Washington, DC).10e14 ViroSeq is
a PCR-based DNA sequencing technique requiring a full-
scale sequencer with multiple primers. It requires an initial
preparation of a plasma sample using a viral RNA isolation
kit, followed by RNA reverse transcription, DNA PCR
ampliﬁcation, and sequencing ampliﬁed products using
ViroSeq equipment in preparation for data analysis. Simi-
larly, TRUGENE is an approved DNA sequencing-based
technique, targeting the protease and reverse transcriptase
(codons 40 to 247). Both methods require an HIV VL in the
range of 2000 to 750,000 copies/mL13,15 for successful
ampliﬁcation and resistance detection, and both can detect
K103N mutations in samples containing approximately 20%
to 25% K103N variants.16
Recent research-only assays have been developed to increase
the sensitivity of resistance detection, which seems to be im-
portant for clinical care.17 Such assays include next-generation
sequencing, pyrosequencing,18 allele-speciﬁc PCR,15,19e21 and
single-genome sequencing,22 which can detect resistance
mutations at levels as low as 0.1%. Despite high sensitivity,
pyrosequencing and single-genome sequencing are costly and
time-consuming, requiring sequencing of multiple genomes.
Allele-speciﬁc PCR is mutation speciﬁc and limited by occur-
rences of false negatives from nucleotide polymorphisms that
can destabilize primer binding. Other novel approaches use
ligation of probe molecules as an indicator of mutation detec-
tion.23 Ligation ampliﬁcation depends on two single-stranded
DNA probes hybridizing adjacently to a target mutation
sequence. In addition to PCR ampliﬁcation, rolling circle
ampliﬁcation is also used in conjunction with this ligation
approach.24 These and other approaches have been shown to
be effective and sensitive, but may have limited functionality in
diverse HIV-1 genomes because of the variability of target
sequences, resulting in mismatch recognition and inherent
copying error of the amplicon during PCR ampliﬁcation25 and
loss of speciﬁcity. The previously mentioned commercial and
noncommercial techniques can sensitively detect HIV resis-
tance mutations, such as K103N; however, they still require
laboratory infrastructure and expertise, which are limited in
RLS. The application of a new method in RLS will require402comparable sensitivity to existing methods with reduction of
duration of sample-to-result time and less equipment restric-
tions based on the ampliﬁcation technique.
Most of the previously mentioned drug-resistance detection
techniques depend on PCR or another form of temperature
cycling. PCR requires expertise and equipment, and can be
challenging when amplifying a small population of mutant
viral sequences due to non-speciﬁc ampliﬁcation. As an alter-
native, nucleic acid sequence-based ampliﬁcation (NASBA),
used in HIV VL testing, can be faster than PCR for certain
RNA ampliﬁcation and compares favorably with PCR for HIV
RNA detection.10,26,27 Because NASBA is an isothermal and
exponential process, it avoids rapid degradation of enzymes
and undesirable hybridization of participating nucleic acids.28
NASBA also has its limitations; it can be limited by the
secondary structure of RNA, making primer design and mul-
tiplexing difﬁcult. Clinically relevant hybridization sites on
long RNA strands may require stringent oligonucleotide
design, with only a small fraction of sequences hybridizing
efﬁciently to RNA, thus reducing the efﬁciency of the ampli-
ﬁcation process.29 To combat these issues, NASBA usually
begins with a 65C heating step before the addition of enzymes
to disrupt full-length RNA secondary structure30 and expose
primer binding sites, typically 100 to 250 nucleotides apart, to
avoid products with an inhibitory secondary structure.31 An
additional disadvantage is the fact that NASBA initiates with
a noncyclic reverse transcription phase, resulting in a relatively
long initial step.32 NASBA has been used in a variety of
noncommercial HIV-1 VL assays27,33,34 and in commercially
available kits, such as the NASBA HIV-1 RNA QT ampliﬁ-
cation system35 or the NucliSens HIV-1 QT36 and its updated,
more rapid, convenient, and reliable version, NucliSens
EasyQ.37 However, the NASBA principle has not been used in
detection of drug-resistant mutations.
Herein, we re-introduce and implement a new approach38
for mutation detection, termed simple method for amplifying
RNA targets (SMART), and use the common K103N as
a model HIV-1 drug-resistant mutation. SMART is a signiﬁ-
cant deviation from currently usedmethods (namely, PCR and
NASBA), speciﬁcally focused on cost-constrained and low
laboratory infrastructure settings. Figure 1 provides an over-
view of the processes in SMART,which are further detailed in
our previous article38 and in the supplemental materials.
SMART incorporates the advantages of microﬂuidics and
avoids the limitations of NASBA. This goal is achieved by
incorporating a binding step and amicroﬂuidic separation step,
which allow the hybridization sites to be located anywhere
along the RNA target. As the basis of the new approach,
SMART ampliﬁcation and detection do not depend on target
RNA variability, but rather on the speciﬁc hybridization of
a small single-strandedDNAprobe termed theSMARTprobe.
This article describes the use of SMART in detecting the
K103N drug-resistance mutation, both on and off chip, with
synthetic HIV-1 model sequences, establishing the ground-
work for drug-resistance monitoring and VL assays in clinical
samples.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 1 Overview of SMART. 1) RNA sample is
isolated from a clinical sample and put into a TE
buffer solution. 2) Streptavidin-coated beads
conjugated with biotinylated capture oligonucleo-
tides and SMART probes are added to the solution.
3) The solution is added to W1 of the SMART
microchip, and a magnet is used to separate the
bead-bound complex from the unbound structures.
4) SMART probes are ampliﬁed via a modiﬁed
NASBA scheme. 5) Sample is quantiﬁed in real-time
using molecular beacons.
SMART Detection of HIV Drug ResistanceMaterials and Methods
Engineered Oligonucleotide Sequences
To design a comprehensive set of sequences that would
represent the high variability of the HIV-1 K103N region,
which is present in multiple HIV-1 subtypes and recombi-
nant forms,39 we used a curated aligned data set of 300
K103N and 6100 wild-type (WT) sequences, obtained from
the nonsubtype B working group data set.40
The diverse regions adjacent to RT position 103 were
examined in this multieHIV-1 subtype data set, and the
most conserved K103N mutated (50-AGAACAAATCGG-
TAAC-30) and WT (50-AAAAAGAAAAAATCAGTAA-
CA-30) sequences were determined, covering approximately
75% of K103N and approximately 60% of WT sequences.
One K103N sequence and one WT sequence were chosen,
both containing these conserved sequences, respectively. A
relevant portion of these individual sequences (approxi-
mately 30 nucleotides that include the respective conserved
sequences) were used to engineer K103N and WT synthetic
DNA (sDNA) fragments.
In subsequent experiments, additional sequences will be
used to cover 100% of mutant and WT variants. The K103N
sDNA used (Table 1) was in a Tris-EDTA buffer solu-
tion and contained two distinct sequences representing
a conserved region (50-ATGGGTGCGAGAGCGTCAA-
TATTAAG-30; capture oligo) of the HIV-1 gag gene, which
is biologically upstream of the K103N region; and a K103N
mutation region sequence (50-CAGGGTTAAAGAAGAA-
CAAATCGGTAACAG-30; SMART probe). These two
regions were separated by 10 adenine oligonucleotides to
give ample space for hybridizations of the capture oligo andThe Journal of Molecular Diagnostics - jmd.amjpathol.orgSMART probe. Table 1 similarly provides the WT sDNA
sequence, SMART probes, primers, molecular beacon
sequences, and nucleotide length of these model sequences.
All of these custom oligonucleotides were purchased from
Integrated DNA Technologies, Inc. (Coralville, IA). Table 1
also shows the K103N and WT RNA reverse complement
(RC) sequences.Theoretical Hybridizations
Theoretical hybridizations of sDNA to biotinylated oligos,
sDNA to SMART probes, beacon dimers, and beacon to
target RNA RC were calculated using the DINAMelt
and mFold Web Server software version 3.1 (DINAMelt
Server; RNA Institute, The State University of New York at
Albany, Albany, NY; http://mfold.rna.albany.edu, last
accessed July 1, 2011), for reaction conditions: temper-
ature Z 41C, [Naþ] Z 70 mmol/L, and [Mg2þ] Z 12
mmol/L. Oligonucleotide hybridizations are characterized
by two properties: the Gibbs free energy (DG), where
a more negative DG value represents a more energetically
favorable state (higher probability of hybridization), and the
melting temperature of the hybrid at which 50% of the
structures will be unhybridized. The probability of
hybridization can be expressed as follows: P f exp( DG/
RT ) where R Z a rate constant and T Z hybridization
temperature (constant). This equation shows that a more
negative DG exponentially increases the probability of
hybridization. Probes and targets were designed to effec-
tively hybridize while avoiding non-speciﬁc hybridizations.
The theoretical hybridization energy of probes and targets
is shown in Supplemental Table S1.403










Biotinylated oligo 50-5BioTEG/CTTAATATTGACGCTCTCGCACCCAT-30 26
K103N SMART probe 50-TCAAGAGTAGACACCTGTTACCGATTTGTTCTTCTTTAACCCTG
GTAATCAGATCAGAGCAATAGGTCA-30
69
WT SMART probe 50-ACTAGCCTTCACGGTGTTACTGATTTTTTCTTTTTTAACCCTG
GTAATCAGATCAGAGCAATAGGTCA-30
68
Primer sequence 1 (K103N þ WT) 50-taatacgactcactatagggTGACCTATTGCTCTGATCTGATTAC-30 45
Primer sequence 2 (K103N) 50-TCAAGAGTAGACACCTGTTACCGAT-30 25
Primer sequence 3 (WT) 50-ACTAGCCTTCACGGTGTTACTGATT-30 25
K103N RNA RC 50-TGACCTATTGCTCTGATCTGATTACCAGGGTTAAAGAAGAACAA
ATCGGTAACAGGTGTCTACTCTTGA-30
69
WT RNA RC 50-TGACCTATTGCTCTGATCTGATTACCAGGGTTAAAAAAGAAAA
AATCAGTAACACCGTGAAGGCTAGT-30
68
Beacon 1 (K103N) 50-/6-FAM/cgcgTCAAGAGTAGACACCTGTTACCGATcgcg/3IABlk_FQ/-30 33
Beacon 2 (WT) 50-/Cy5/cgcgACTAGCCTTCACGGTGTTACTGATTcgcg/3IABlk_FQ/-30 33
The single-stranded K103N sDNA sequence was designed with a mutated sequence (boldfaced) centered about the K103N codon (underlined), and the single-
stranded WT sDNA sequence was designed with a nonmutated sequence (plain text) centered about the nonmutated lysine codon (underlined) (repetition of that
previously described). Poly(A) sequences (lowercased) ﬂanking the target regions extend the sDNA sequence to simulate the longer viral RNA sequence occurring
in nature, and the poly(A) sequences in the middle simulate the sequences that are between the capture and target region in nature. K103N and WT SMART probes
have hybridization regions (boldfaced) with their respective sDNA targets and a primer 1 region (underlined). Primer 1 was designed to hybridize with both probes
(underlined) and contains a T7 promoter region (lowercased). Primer 2 (K103N) and primer 3 (WT) were designed to hybridize (boldfaced and underlined) with the
K103N RNA RC and the WT RNA RC, respectively, and all potential SMART probe variations. Beacon 1 (K103N) and beacon 2 (WT) were also designed to
competitively hybridize with the same regions (boldfaced and underlined) of the K103N RNA RC and the WT RNA RC, respectively. Again, this is to ensure that only
one K103N beacon and one WT beacon are necessary for all variations of K103N and WT probes. The stem-loop region of each beacon is lowercased.
Morabito et alMicrochip Device
The microchip was constructed using a glass substrate and
a polydimethylsiloxane layer containing microchannels and
reservoirs. The microchip design (Supplemental Figure S1B) is
a simple four-channel device (onechannel per sample), inwhich
each channel is tapered and designed for adequate separation of
conjugated magnetic beads from unbound SMART probes
using a magnetic bar. The microchip can process four samples
simultaneously. The 2.8-mm diameter M-280 magnetic beads
were obtained from Invitrogen (Carlsbad, CA).
NASBA Reaction Mix
The reagents used for NASBA and their concentrations at
the ﬁnal reaction volume were 40 mmol/L Tris (pH 8.0),
12.5 mmol/L MgCl2, 73.5 mmol/L CH3COOK, 5.25 mmol/
L dithiothreitol, 1.05 mmol/L dNTP, 2.1 mmol/L rNTP,
0.21 mmol/L each primer, 52.5 nmol/L molecular beacon,
15.75% dimethyl sulfoxide, 1.68 m/mL T7 RNA polymerase,
0.34 m/mL AMV-RT, 0.005 m/mL RNase-H, and 0.11 mg/mL
bovine serum albumin. Enzymes and reagents used were
purchased from Promega (Madison, WI).
Heating Devices
For on-chip ampliﬁcation, an external RK-80H power supply
(MatsusadaPrecision Inc.,KusatsuCity, Shiga, Japan) provided4044 to 5V to theMincoﬂexible transparent heater to achieve 41C
inwell 2 of themicrochip.Wevalidated the heating temperature
using a thermocouple attached to our microchip wells.
For off-chip real-time ampliﬁcation and detection, we
used a single cuvette peltier (Photon Technology Interna-
tional, Birmingham, NJ); and for off-chip ampliﬁcation
followed by off-chip end point gel electrophoresis, we used
a C1000 thermal cycler (Bio-Rad, Hercules, CA).
Optical Equipment
For on-chip real-time detection, we used a Nikon Eclipse
TE2000-U ﬂuorescent microscope (Nikon Instruments, Inc.,
Melville, NY) with a blue ﬁlter set for 6-carboxyﬂuorescein
(450- to 490-nm excitation, 515-nm long-pass emission),
a red ﬁlter set for Cy5 (590- to 650-nm excitation, 663- to
738-nm band-pass emission), a 4 objective, a model 814
Photomultiplier Detection System with a gain of 700 V
(Photon Technology International), and an integrated high-
speed shutter (Melles Griot, Albuquerque, NM) set to open
for 0.2 seconds. A custom in-house LabVIEW (National
Instruments Corporation, Austin, TX) data acquisition
program collected photomultiplier tube output at a rate of
12 to 15 Hz.
For off-chip real-time detection, samples were prepared in
disposable Uvettes (Eppendorf AG,Hamburg, Germany), and
real-time ﬂuorescence was measured using a Quantamasterjmd.amjpathol.org - The Journal of Molecular Diagnostics
SMART Detection of HIV Drug Resistancespectroﬂuorometer (Photon Technology International, Bir-
mingham, NJ).
SMART Experiments
K103N and WT sDNA samples with a concentration ranging
from 6  108 to 6000 copies/mL were used. This range of
VLs is only two orders of magnitude higher than the range of
detection of most commercially available HIV-1 VL assays
(107 to approximately 50 copies/mL),10 thus most of these
starting concentrations of sDNA are clinically relevant.
Biotinylated oligos, sDNA sample, SMART probes, mag-
netic beads, and hybridization buffer were incubated for
30 minutes before loading onto the microchip. The poly-
dimethylsiloxane chip was prewashed with nuclease decon-
tamination solution (Integrated DNA Technologies) and
presoaked with hybridization buffer (Tris, MgCl2, NaCl,
Tween-20, and bovine serum albumin). Microﬂuidic sepa-
ration occurred after the incubation as biotinylated oligos,
sDNA sample, SMART probes, magnetic beads, and hy-
bridization buffer were added to well 1 (W1; Figure 1) and
moved through the channel by moving a neodymium mag-
net along the bottom of the channel at approximately 0.6 mm/
second toward well 2 (W2; Figure 1). To ensure that beads
would not clog channels, an optimized concentration of 0.05
mg/mL was used. On-chip or off-chip ampliﬁcation was then
performed for 180 minutes at 41C, described later. Although
on-chip detection can be performed by integrating a better
detection system, we used off-chip detection because the
ﬂuorometer was already equipped for more accurate, higher-
sensitivity ﬂuorescence detection, allowing us to better gauge
the sensitivity of our assay.
Although real-time ampliﬁcation analysis was performed
with molecular beacons, end point analysis of ampliﬁcation
products was performed with gel electrophoresis via a 2100
Bioanalyzer Small RNA Assay (Agilent Technologies,
Marshﬁeld, MA).
On-Chip Ampliﬁcation
At the conclusion of the separation step, the magnetic bead
complexes were <1 cm from W2 and the ﬂow was manually
stopped by the removal of solution in both W1 and W2 and
the addition of 12mL of parafﬁn oil toW1 to avoid evaporation
of reagents. The NASBA reaction mix was then introduced
for on-chip ampliﬁcation (total volume, 5 mL) and the on-chip
ampliﬁcation apparatus was connected. On-chip ampli-
ﬁcationwas used to preliminarily demonstrate the ability of the
assay to be used as a point-of-care (POC) device.
Off-Chip Ampliﬁcation
At the conclusion of the separation step, the magnetic bead
complex was moved into W2. Then, the W2 contents were
transferred into a polypropylene tube and W2 was rinsed
with an additional 6 mL of hybridization buffer. The beadsThe Journal of Molecular Diagnostics - jmd.amjpathol.orgwere then collected at the bottom of the tube, and all but
2 mL of solution was removed for off-chip NASBA
ampliﬁcation using a ﬂuorometer. Fluorescence readings
were taken every 5 minutes to yield real-time ﬂuorescence
data. Off-chip ampliﬁcation used the same ratio of NABSA
reaction mix as on-chip ampliﬁcation, with a larger total
solution volume of 80 mL.Results
The SMART probe can be engineered speciﬁcally to have
favorable or unfavorable binding energies (eg, ensuring it does
not bind to other oligonucleotides in the mix). SMART
requires only single-time diffusion and binding of small
molecules (SMART probes) into the RNA structure. Hence,
diffusion is fast and less dependent on the RNA structure itself
than in traditional NASBA. The ampliﬁcation step of SMART
uses an abridged version of NASBA, starting with the short
SMARTprobeDNA template rather than the actual longRNA
template. This crucial design feature completely eliminates the
noncyclic reverse transcription phase of NASBA and uses
a small amplicon (100 nucleotides) compared with traditional
NASBA or PCR for amplifying RNA, resulting in faster and
more accurate ampliﬁcation and detection. SMART can be
performed on a closed microﬂuidic chip device that uses
isothermal heating in low temperature (41C) without thermal
cycling or preheating, thus driving cost down. In this prelim-
inary work, we used sDNA in place of clinical HIV RNA
samples, to establish the feasibility of this method. Future
work will integrate isolation of RNA from clinical samples
from HIV-infected patients.Validation of SMART Using On-Chip Ampliﬁcation
SMART experiments were initially performed for K103N
detection using capture, separation, and on-chip ampliﬁca-
tion for 180 minutes at 41C, followed by off-chip end point
gel electrophoresis. End point detection was used rather than
real-time detection to validate the capture and separation
steps, ensuring that the correct size oligonucleotide was
ampliﬁed and visible in the gel plot. In addition, to evaluate
the effect of the molecular beacons, ampliﬁcation was per-
formed with (Bþ) and without (B) beacons, to investigate
if there was any inhibitory effect on ampliﬁcation.
Figure 2A summarizes the outcomes of the experiment,
conﬁrming that capture, separation, and ampliﬁcation reac-
tions were occurring as expected. K103N probe RC was
expected to be approximately 69 nucleotides. The dark
bands in the K103N-positive lanes (1, 2, 6, and 7) corre-
spond to this product. This K103N probe RC band also
occurred in K103N-negative lanes (3, 4, 5, 8, 9, and 10), but
at light intensity (low concentration), likely because of low
concentrations of K103N probe carryover during separation,
which was expected.38 This minimal probe carryover limits
the sensitivity of our assay, and we are exploring ways to405
Figure 2 A: SMART gel plot after on-chip ampliﬁcation for 180 minutes, showing the detection of K103N sDNA at different concentrations (lanes 1, 2, 6, and
7), using a K103N probe in the absence (B) or presence (Bþ) of beacons. No DNA (lanes 3 and 8) and low and high concentrations of WT single-stranded DNA
(lanes 4, 5, 9, and 10) were also included as negative controls for detection with a K103N probe. B: SMART electropherogram of the gel plot shown in A, showing
that the addition of molecular beacons has a signiﬁcant inhibitory effect on probe ampliﬁcation, especially for low starting concentrations of K103N sDNA.
Morabito et alfurther reduce carryover for even greater sensitivity. Light
bands also occurred at approximately 45 and approximately
22 nucleotides, likely attributed to the primers used. An
unexpected band of light intensity (approximately 60 nucle-
otides) may have been generated as the polymerase prema-
turely aborted transcription, resulting in RNA RC products
that are shorter than expected. This prematurely aborted
transcription was also observed in previous work38 and does
not have a negative impact on the assay sensitivity. Corre-
sponding electropherographic data (Figure 2B) showed, as
expected, that high starting concentrations of K103N sDNA
yielded the highest ﬂuorescence signal and that controls with
no DNA and WT exhibited minimal ﬂuorescence.
Interestingly, the addition of molecular beacons had
a signiﬁcant effect on the ampliﬁcation, particularly at the
low concentration. In Figure 2B, the area under the curve for
the starting concentration of 6  108 copies/mL declined
approximately 10% (lane 1 to lane 6) with the addition of
beacon while decreasing approximately 45% for 6  106
copies/mL (lane 2 to lane 7). This suggests that beacon is
not only inhibitory to the ampliﬁcation cycle, but also that
inhibitory events are more pronounced at lower K103N
probe concentrations. A lower starting concentration of
K103N sDNA yields less hybridized K103N probe, as
evident in the electropherogram when comparing 6  108
and 6  106 copies/mL, making the starting concentration
of available K103N probe template for the NASBA cycle
lower. Because the ampliﬁcation cycle is exponential, the
suggested inhibitory events are of a greater magnitude at
lower K103N probe concentrations. This is directly sup-
ported by the data when comparing end point ampliﬁcation.
Validation of SMART Using Off-Chip Ampliﬁcation with
Real-Time Detection
On veriﬁcation of the ampliﬁed product using end point
detection, by interpreting the gel plot (Figure 2A) and406electropherogram (Figure 2B), SMART ampliﬁcation was
performed off chip for real-time K103N detection. Figure 3A
shows the real-time results. First, the exponential curves
plateau toward a maximum because the ﬂuorescence repre-
sents the beacons hybridizing with the amplifying K103N
RNARC, in the presence of a limited amount (52.5 nmol/L) of
molecular beacons in the reaction mix. For the high concen-
tration (6  108 copies/mL), 90 minutes of ampliﬁcation
yielded distinguishable detection versus the controls, with the
ampliﬁcation curve crossing the threshold of detection [ie,
time to positivity value (Tp) in 45 minutes]. For the lower
concentrations (6 106 through 6000 copies/mL), this level of
detection was achievable but required more time for ampliﬁ-
cation, consequently higher Tp or equivalent CT values. From
these results, we plotted a linearmodel of Tp versus copies/mL
(logarithmic scale), shown in Figure 3B. Figure 3C shows an
end point analysis of our results, offering a clear illustration of
all K103N concentrations tested to bewell above the threshold
of detection after 180 minutes of ampliﬁcation.
Determining K103N Concentration Using SMART Probes
As a ﬁnal implementation step, we evaluated SMART as an
effective means for estimating K103N concentrations of
unknown samples. The objective of this approach was to
establish that we can simultaneously amplify and detect
a multiple beacon system and that our SMART probes may
be used in such a system as standards to determine K103N
concentration of an unknown sample. We considered
a group of samples with variable concentrations of WT and
K103N SMART probes. We used a total of 1 pmol/L (6 
108 copies/mL) of SMART probes (K103N þ WT) to
evaluate the efﬁcacy of our assay to generate linear models
based on K103N SMART probe concentrations. A variety
of K103N SMART probe concentrations were used as our
known standards and ranged from 100% (6 108 copies/mL)
to 1% (6  106 copies/mL).jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 3 SMART assay results using off-chip ampliﬁcation with real-time detection. A: WT sDNA and no DNA negative controls were included and plotted as
background ﬂuorescence (gray area). WT-speciﬁc SMART probes, WT primers, and WT molecular beacon were not included in this assay. The dashed black line
indicates the threshold of detection or Tp for positive samples. SD was within 5% of results (error bars not shown). B: The Tp values are plotted versus the
logarithmic scale of starting K103N sDNA concentration. SD was within 5% of results (error bars not shown). C: Histogram of normalized ﬂuorescence of all
sDNA and controls after 180 minutes’ reaction time. SD was within 5% of results (error bars not shown).
SMART Detection of HIV Drug ResistanceFigure 4 shows the off-chip real-time detection of the
K103N probe within varying K103N-WT probe samples.
There was no considerable change in baseline K103N beacon
ﬂuorescence for samples containing no DNA and for a sample
containing onlyWT probe, conﬁrming that the K103Nbeacon
was stable and highly speciﬁc to its intendedK103NRNARC
target. As the starting percentage of K103N probe increased,
so did the rate of ﬂuorescence. With a higher starting con-
centration of the K103N probe, the reaction produced more
K103N RNA RC in a given amount of time. Therefore, with
higher starting concentrations of K103N probes, there was
faster hybridization of K103N beacons with the K103N RNA
RC targets. This correlation can also be explained in its
converse; as the starting concentration of K103N probes
decreased, the resulting exponentialﬂuorescence curve shifted
with increasing time. These data correspond to the real-time
SMART results shown in Figure 3A, in which a higher
concentration of starting K103N sDNA yielded more K103N
probe, which, in turn, resulted in faster ampliﬁcation.
Figure 5 similarly shows the off-chip real-time detection
of the WT probe within varying K103N-WT probe samples.
There was no change in baseline WT beacon ﬂuorescence
for samples containing no DNA and for a sample containing
only K103N probe, conﬁrming that the WT beacon was
stable and highly speciﬁc to its intended WT target. For
samples containing 50% to 100% WT probe, the WT
beacon ﬂuorescence increased exponentially, reaching its
beacon-limited maximum after approximately 45 minutes.
These data indicate that the WT beacon hybridized effec-
tively with high concentrations of WT RNA RC target;
however, the concentrations were too high to achieve any
distinguishable resolution between the varying concentra-
tions of probe in this time scale. This suggests that SMART,
as it is designed, is not ideal for distinguishing concentra-
tions >3  108 copies/mL. This gives us a ballpark numberThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfor the upper VL limit of our assay, which compares well
with commercially available VL kits (approximately 107
copies/mL).
These off-chip data sets were then used to generate model
ﬁts capable of predicting starting K103N probe concentra-
tions by standardizing, rearranging, and plotting the real-
time ﬂuorescence data. Figure 6A shows the model for high
concentrations (3  107 to 1.5  108 copies/mL) of
K103N SMART probes. For high starting concentrations,
we were able to resolve ﬂuorescence at an early time point
during the ampliﬁcation (45 minutes). These data ﬁt a linear
curve that can be used to interpolate for unknown high
K103N SMART probe starting concentrations based on
these measured ﬂuorescence standard values. For low con-
centrations (<3  107 copies/mL) (Figure 6B), we are able
to resolve the variations at a later time point during the
ampliﬁcation (90 minutes). These data ﬁt a linear curve that
can be used to interpolate for unknown low K103N SMART
probe starting concentrations based on measured ﬂuores-
cence values. These data also show that K103N beacons
hybridized effectively with high and low concentrations of
K103N RNA RC target.
For the case of on-chip ampliﬁcation, each polydimeth-
ylsiloxane chip contained four identical channels, such that
three samples of knownK103N concentration could be run in
parallel with one unknown sample. However, to establish our
theoretical model, we used all four channels with known
sample quantities. Figure 7, A and B, shows similar plots for
on-chip modeling.Discussion
Herein, we present a novel method for RNA mutation
detection, and apply it to HIV-1 drug-resistance407
Figure 4 Off-chip real-time ﬂuorescence of ampliﬁed K103N probe as
a function of time. Total concentration of SMART probes (K103N þ WT)
were 1 pmol/L (6  108 copies/mL). SD was within 5% of results (error bars
not shown). Background ﬂuorescence is shown as a shaded gray area.
Figure 5 Off-chip real-time ﬂuorescence of ampliﬁed WT probe as
a function of time. Total concentration of SMART probes (K103N þ WT) was
1 pmol/L (6  108 copies/mL). SD was within 5% of results (error bars not
shown). Background ﬂuorescence is shown as a shaded gray area.
Morabito et aldetermination. We captured, separated, ampliﬁed, and
detected target mutated and WT sDNA sequences resem-
bling an HIV-1 RT commonly mutated region, and engi-
neered ampliﬁable SMART probes for optimal reaction
kinetics rather than amplifying the target sDNA itself, using
both off-chip and on-chip ampliﬁcation and detection
systems. We show that the initial 65C step of NASBA can
be removed because of our novel design, making the
ampliﬁcation fully isothermal, thus providing signiﬁcant
advantages in ﬁeld-deployable and other POC settings. The
hybridization of both a biotinylated oligonucleotide and an
ampliﬁable SMART probe, instead of primers, maintained
the speciﬁcity of the assay when compared with traditional
methods of mutation detection. Also, the use of magnetic
beads instead of a tube-based multiple wash kit allowed for
simple and efﬁcient separation of the target-bead complex
from unbound SMART probe. A simple microﬂuidic device
to facilitate separation of the ampliﬁable SMART probes
was incorporated, avoiding the need for a ﬂow apparatus or
major heating component. This resulted in a signiﬁcantly
reduced assay cost and is a promising practical platform for
POC use.
Existing methods for HIV resistance mutation detection
are not intended for POC use. In addition, existing detection
methods potentially suitable for POC use do not incorporate
drug-resistance mutation determination. Sensitive commer-
cial VL nonmicroﬂuidic assays are not speciﬁcally designed
to detect drug-resistance sequences and appear to lack the
practicality for POC settings. Microﬂuidic methods, which408are only developed using immunobased chemistry, are
promising VL methods for POC use, but fail to address
drug-resistance monitoring.10 Many drug-resistance muta-
tion detection assays either are commercially available (e.g.,
TRUGENE and ViroSeq) or used in the research setting
(e.g., pyrosequencing, single-genome sequencing, allele-
speciﬁc PCR, and ligation ampliﬁcation), but they are not
yet fully viable for POC and do not take advantage of
microﬂuidics. SMART is a promising means of merging
these methods for POC settings, using a simple microﬂuidic
platform for detecting resistance-mutant sDNA with
high speciﬁcity and distinguishing between mutant/WT
sequences simultaneously. With further development,
SMART could be used as a VL monitoring technique in
addition to determining the concentration of resistance
mutations such as K103N within a given sample.
In our experiments, we observed that the addition of
molecular beacons had a signiﬁcant effect on ampliﬁcation,
particularly at lower concentrations. This is likely attributed
to the combination of two inhibitory events: the competition
between primer 2 and beacon 1 during the ampliﬁcation cycle
and the premature abortion of T7 polymerase. McCalla et al38
reported that the premature abortion did not affect their
detection methods because the beacon targeted the middle of
the transcribed inﬂuenza RNA. However, herein, the beacon
targeted the end of the transcribed RNA, which would result
in decreased beacon-RNA hybrids for the prematurely
aborted RNA products. Several smaller peaks in the elec-
tropherogram support this suggestion. Targeting the end of
the RNA, rather than the middle, negatively affects the speed
of the assay, but is a necessary assay design trade-off for
simultaneous detection of many K103N SMART probes
while only using two primers and one molecular beacon.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 6 Off-chip modeling of ﬂuorescence versus K103N SMART probe
concentration at high concentrations (3  107 to 1.5  108 copies/mL
K103N SMART probe) (A) and low concentrations (3  107 copies/mL
K103N SMART probe) (B).
Figure 7 On-chip modeling of ﬂuorescence versus K103N SMART probe
concentration at high concentrations (3  107 to 1.5  108 copies/mL
K103N SMART probe) (A) and low concentrations (3  107 copies/mL
K103N SMART probe) (B).
SMART Detection of HIV Drug ResistanceResults of the Bþ versus B experiments supported our
hypothesis that a beacon-free system would amplify larger
quantities of product. By our design, the beacons were in
competition with Seq2 and Seq3 primers (Table 1) to
hybridize with the RNA RC products during NASBA
(Supplemental Figure S1C). When comparing the K103N
samples containing 6  108 copies/mL, we saw approxi-
mately a 12% increase in ﬂuorescence when the beacon was
removed. For K103N samples containing 6  106 copies/mL,
we saw approximately a 50% increase when the beacon was
removed. This suggests that the beacon is inhibitory to the
ampliﬁcation cycle and supports the argument that inhibitory
events are of a greater magnitude at lower K103N probe
concentrations.
Nonetheless, the beacons are essential for detection in our
assay and our POC design criteria; thus, the purpose of thisThe Journal of Molecular Diagnostics - jmd.amjpathol.orgcomparison was to better understand the kinetics of the
system, not to reach a decision point to eliminate or keep the
molecular beacons. Rather than remove beacons from our
one-step master mix, we seek to further optimize the
NASBA buffer conditions for faster ampliﬁcation and
reduce carryover of unbound SMART probes for greater
speciﬁcity. Although the sensitivity of 6000 copies/mL,
shown herein, must be improved before clinical use, this
work successfully establishes the feasibility of using a new
technique (SMART) for detection of drug-resistance muta-
tions, such as K103N.
The results of our real-time off-chip ampliﬁcation experi-
ments indicate that detection for lower target concentrations
(6 106 through 6000 copies/mL) is achievable, but requires
longer ampliﬁcation times and, consequently, higher Tp or
equivalent CT values. This strongly suggests that detection is
possible for low, clinically relevant concentrations of K103N
(1000 copies/mL) using SMART. A slightly longer
ampliﬁcation time is required (approximately 4 hours) to409
Morabito et alachieve comparable results in lower concentrations, although
Tp is achievable within 180 minutes. Off-chip ampliﬁcation
achieved a much greater degree of sensitivity than could be
achieved using on-chip optics, demonstrating the greatest
sensitivity of our assay as it stands. From our linear model
(Figure 3B) of Tp versus copies/mL (logarithmic scale), the
current SMART assay is theoretically sensitive enough to
detect as low as 1000 copies/mL of K103N sDNA.
By using the real-time ﬂuorescence data from known
standards (ie, samples with known K103N SMART probe
concentrations), we were able to accurately predict the
K103N probe concentration (copies/mL) of an unknown
multiprobe sample. Off-chip ampliﬁcation was used to
establish this method of modeling, with a greater degree
of sensitivity than could be achieved with on-chip
ampliﬁcation. However, the off-chip ampliﬁcation was
a less practical method because we could only amplify
one sample at a time and required a cuvette. On-chip real-
time detection of sDNA samples required a small (only 5
mL) amount of reaction volume, as opposed to conven-
tional PCR volumes, which usually start at a minimum of
20 mL. The small reaction volume concentrated the target
and probe molecules, which may have decreased the time
to positive results. Linear models for on-chip ampliﬁca-
tion were produced, but with a larger SE, resulting in
reduced speciﬁcity of the on-chip model.
Through this study, we were able to observe the limi-
tations of SMART. First, the use of molecular beacons
inhibited the ampliﬁcation process, but the Tp values were
similar to commercial and noncommercial PCR-based
techniques. This is, therefore, only a minor issue and
a worthwhile trade-off for the POC attributes that accom-
pany the use of molecular beacons. Second, SMART assay
design parameters may be adapted and further optimized
for smaller Tp values that would reduce the reaction time
beyond existing techniques. Third, SMART at its current
stage lacks an integrated isolation step. This is an impor-
tant aspect of its POC applicability and is in development.
Fourth, the optics used for detection were laboratory grade,
and a transition to ﬁeld-deployable optics to achieve full
POC and RLS status is still needed. Fifth, we only
demonstrated SMART to be effective for targeting one
K103N and one WT sequence. Future work will include
assaying multiple sequences simultaneously to further
prove the validity and applicability of our design. Last, the
sensitivity of SMART is within the commercially relevant
range (2000 to 10,000,000 copies/mL), but additional work
is needed to improve the sensitivity to match the lower VL
limit of commercial kits (approximately 50 copies/mL),
and for sensitive detection of drug-resistance mutations.
We anticipate achieving greater sensitivity by incorpo-
rating our own on-chip isolation technique, in which larger
volumes of starting sample containing RNA will be pro-
cessed and concentrated into a smaller volume. This would
effectively increase the VL, a beneﬁt that our synthetic
samples did not have.410In summary, we introduce a novel HIV drug-resistance
detection assay and show that it can theoretically detect,
quantify, and estimate unknown HIV RT K103N concentra-
tions. These methods and platform have great potential for
their eventual application to clinical, global HIV care. In our
study, we demonstrated that sDNA, based on actual K103N
and WT HIV-1 viral RNA sequences, hybridized efﬁciently
with SMART probes at clinically relevant concentrations. In
addition, the sample-to-result time of our assay meets or
improves on most commercially available assays.10 The
ﬂexibility of the SMART probe sequence allows this method
to be easily adopted for other HIV drug-resistance mutations.
Moving forward, wewould like to achieve similar results with
clinical HIV samples, incorporate the RNA isolation step, and
use RLS capable optics, such as light-emitting diodes and
suitable cameras. Our ultimate goal of providing costly,
timely, and effective POC HIV quantiﬁcation and drug-
resistance detection methods in RLS, with no mandatory
laboratory support, will allow clinicians to more adequately
and effectively treat HIV-infected patients, whether before or
after exposure to antiretroviral therapy. In our future work, we
will apply these methods to clinical HIV-1 samples, other
RNA targets, such as the inﬂuenza virus, and biothreats.
Doing so will require extensive optimization of our assay so
that it is tuned to overcome the technical challenges in
sensitivity and speciﬁcity that clinical samples may present.
Acknowledgments
We thank The RNA Institute, College of Arts and Sciences,
The State University of New York at Albany, for use of their
DINAMelt web server; Stephanie McCalla, Aartik Sarma,
and Carmichael Ong for their previous work inventing
SMART and developing the technology; and Dr. Mia Coet-
zer for scientiﬁc contribution and technical assistance.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2013.02.005.
References
1. Levy JA, Autran B, Coutinho RA, Phair JP: 25 Years of AIDS:
recording progress and future challenges. AIDS 2012, 26:1187e1189
2. Clavel F, Hance AJ: HIV drug resistance. N Engl J Med 2004, 350:
1023e1035
3. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R,
Wensing AM, Richman DD: 2011 Update of the drug resistance
mutations in HIV-1. Top Antivir Med 2011, 19:156e164
4. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y,
Sutherland D, Vitoria M, Guerma T, De Cock K: The WHO public-
health approach to antiretroviral treatment against HIV in resource-
limited settings. Lancet 2006, 368:505e510
5. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ,
Richman DD, Pond SLK, Smith DM: Detection of minority resistance
during early HIV-1 infection: natural variation and spurious detectionjmd.amjpathol.org - The Journal of Molecular Diagnostics
SMART Detection of HIV Drug Resistancerather than transmission and evolution of multiple viral variants.
J Virol 2011, 85:8359e8367
6. Gianella S, Richman DD: Minority variants of drug-resistant HIV.
J Infect Dis 2010, 202:657e666
7. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V,
Respess R, Stevens W, Forum for Collaborative HIV Research
Alternative Viral Load Assay Working Group: HIV-1 viral load assays
for resource-limited settings. PLoS Med 2006, 3:e417
8. Chin CD, Laksanasopin T, Cheung YK, Steinmiller D, Linder V,
Parsa H, Wang J, Moore H, Rouse R, Umviligihozo G, Karita E,
Mwambarangwe L, Braunstein SL, van de Wijgert J, Sahabo R,
Justman JE, El-Sadr W, Sia SK: Microﬂuidics-based diagnostics of
infectious diseases in the developing world. Nat Med 2011, 17:
1015e1019
9. O’Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ,
Zahwa H, Bradley WP, Branson BM, Michael NL, De Witt CC:
Performance of the OraQuick rapid antibody test for diagnosis of
human immunodeﬁciency virus type 1 infection in patients with
various levels of exposure to highly active antiretroviral therapy. J Clin
Microbiol 2003, 41:2153e2155
10. Wang S, Xu F, Demirci U: Advances in developing HIV-1 viral load
assays for resource-limited settings. Biotechnol Adv 2010, 28:
770e781
11. Cabrera C, Marﬁl S, Poveda E, Puig T, Bonjoch A, Ziermann R,
Soriano V, Clotet B, Ruiz L: Comparative evaluation of the TRU-
GENE HIV-1 envelope (gp41) genotyping assay on clinical samples.
Antiviral Ther 2005, 10:S48
12. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi CJ,
Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE,
Eshleman SH: Sensitivity of the ViroSeq HIV-1 genotyping system for
detection of the K103N resistance mutation in HIV-1 subtypes A, C,
and D. J Mol Diagn 2006, 8:430e432
13. Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL,
Swanstrom R, D’Aquila RT, Van Gorder M, Holodniy M, Lloyd RM,
Reid C, Morgan GF, Winslow DL: Accuracy of the TRUGENE HIV-1
genotyping kit. J Clin Microbiol 2003, 41:1586e1593
14. Bile EC, Adje-Toure C, Borget MY, Kalou M, Diomande F, Chorba T,
Nkengasong JN: Performance of drug-resistance genotypic assays
among HIV-1 infected patients with predominantly CRF02_AG strains
of HIV-1 in Abidjan, Cote d’Ivoire. J Clin Virol 2005, 32:60e66
15. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Cofﬁn JM,
Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A,
Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S,
Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D,
Mellors JW: Blinded, multicenter comparison of methods to detect
a drug-resistant mutant of human immunodeﬁciency virus type 1 at
low frequency. J Clin Microbiol 2006, 44:2612e2614
16. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ,
Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R,
Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR:
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-
based antiretroviral treatment failure: a systematic review and pooled
analysis. JAMA 2011, 305:1327e1335
17. Li JZ, Paredes R, Ribaudo H, Svarooskaia ES, Kozal MJ, Hullsiek KH,
Miller MD, Bangsberg D, Kuritzkes DR: Relationship between
NNRTI adherence and low-frequency resistance mutations with the
risk of virological failure. Antiviral Ther 2011, 16:A16
18. Wang CL, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW:
Characterization of mutation spectra with ultra-deep pyrosequencing:
application to HIV-1 drug resistance. Genome Res 2007, 17:
1195e1201
19. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S,
Holte S, Naugler WE, Pawluk DM, Li CC, Frenkel LM: Comparison
of oligonucleotide ligation assay and consensus sequencing for
detection of drug-resistant mutants of human immunodeﬁciency virus
type 1 in peripheral blood mononuclear cells and plasma. J Clin
Microbiol 2004, 42:3670e3674The Journal of Molecular Diagnostics - jmd.amjpathol.org20. Gale HB, Kan VL, Shinol RC: Performance of the TruGene human
immunodeﬁciency virus type 1 genotyping kit and OpenGene
DNA sequencing system on clinical samples diluted to approxi-
mately 100 copies per milliliter. Clin Vaccine Immunol 2006, 13:
235e238
21. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, Delwart EL:
Sequencing-based detection of low-frequency human immunodeﬁ-
ciency virus type 1 drug-resistant mutants by an RNA/DNA hetero-
duplex generator-tracking assay. J Virol 2004, 78:7112e7123
22. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H,
Rock D, Falloon J, Davey RT, Dewar RL, Metcalf JA, Hammer S,
Mellors JW, Cofﬁn JM: Multiple, linked human immunodeﬁciency
virus type 1 drug resistance mutations in treatment-experienced
patients are missed by standard genotype analysis. J Clin Microbiol
2005, 43:406e413
23. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR,
Yeo CJ, Hruban RH, Goggins MG, Eshleman JR: LigAmp: sensitive
detection of single nucleotide differences. Nat Methods 2004, 1:
141e147
24. Wang B, Dwyer DE, Chew CB, Kol C, He ZP, Joshi H, Steain MC,
Cunningham AL, Saksena NK: Sensitive detection of the K103N non-
nucleoside reverse transcriptase inhibitor resistance mutation in
treatment-naive HIV-1 infected individuals by rolling circle ampliﬁ-
cation. J Virol Methods 2009, 161:128e135
25. Kobayashi N, Tamura K, Aotsuka T: PCR error and molecular pop-
ulation genetics. Biochem Genet 1999, 37:317e321
26. Dyer JR, Gilliam BL, Eron JJ, Grosso L, Cohen MS, Fiscus SA:
Quantitation of human immunodeﬁciency virus type 1 RNA in cell free
seminal plasma: comparison of NASBA(TM) with Amplicor(TM)
reverse transcription-PCR ampliﬁcation and correlation with quanti-
tative culture. J Virol Methods 1996, 60:161e170
27. Vandamme AM, Van Dooren S, Kok W, Goubau P, Fransen K,
Kievits T, Schmit JC, De Clercq E, Desmyter J: Detection of HIV-1
RNA in plasma and serum samples using the NASBA ampliﬁcation
system compared to RNA-PCR. J Virol Methods 1995, 52:121e132
28. McCalla SE, Tripathi A: Microﬂuidic reactors for diagnostics appli-
cations. Ann Rev Biomed Eng 2011, 13:321e343
29. Luebke KJ, Balog RP, Garner HR: Prioritized selection of oligo-
deoxyribonucleotide probes for efﬁcient hybridization to RNA tran-
scripts. Nucleic Acids Res 2003, 31:750e758
30. Guatelli JC, Whitﬁeld KM, Kwoh DY, Barringer KJ, Richman DD,
Gingeras TR: Isothermal, in vitro ampliﬁcation of nucleic acids by
a multienzyme reaction modeled after retroviral replication. Proc Natl
Acad Sci U S A 1990, 87:1874e1878
31. Deiman B, van Aarle P, Sillekens P: Characteristics and applications of
nucleic acid sequence-based ampliﬁcation (NASBA). Mol Biotechnol
2002, 20:163e179
32. Compton J: Nucleic-acid sequence-based ampliﬁcation. Nature 1991,
350:91e92
33. Gupta P, Mellors J, Kingsley L, Riddler S, Singh MK, Schreiber S,
Cronin M, Rinaldo CR: High viral load in semen of human immu-
nodeﬁciency virus type 1-infected men at all stages of disease and its
reduction by therapy with protease and nonnucleoside reverse tran-
scriptase inhibitors. J Virol 1997, 71:6271e6275
34. van Gemen B, van Beuningen R, Nabbe A, van Strijp D, Jurriaans S,
Lens P, Kievits T: A one-tube quantitative HIV-1 RNA NASBA
nucleic-acid ampliﬁcation assay using electrochemiluminescent (ECL)
labelled probes. J Virol Methods 1994, 49:157e167
35. Vandamme AM, Schmit JC, Van Dooren S, Van Laethem K, Gobbers E,
KokW,Goubau P,WitvrouwM, PeetermansW,DeClercq E, Desmyter J:
Quantiﬁcation of HIV-1 RNA in plasma: comparable results with the
NASBAHIV-1RNAQT and the AMPLICORHIVmonitor test. J Acquir
Immune Deﬁc Syndr Hum Retrovirol 1996, 13:127e139
36. Segondy M, Ly TD, Lapeyre M, Montes B: Evaluation of the
nuclisens HIV-1 QT assay for quantitation of human immunodeﬁ-
ciency virus type 1 RNA levels in plasma. J Clin Microbiol 1998,
36:3372e3374411
Morabito et al37. Yao J, Liu Z, Ko LS, Pan G, Jiang Y: Quantitative detection of HIV-1
RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods 2005,
129:40e46
38. McCalla SE, Ong C, Sarma A, Opal SM, Artenstein AW, Tripathi A:
A simple method for amplifying RNA targets (SMART). J Mol Diagn
2012, 14:328e335
39. Kantor R: Impact of HIV-1 pol diversity on drug resistance and its
clinical implications. Curr Opin Infect Dis 2006, 19:594e60641240. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B,
Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C,
Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P,
Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L,
Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D,
Harrigan PR, Camacho R, Schapiro JM, Shafer RW: Impact of HIV-1
subtype and antiretroviral therapy on protease and reverse transcriptase
genotype: results of a global collaboration. PLoS Med 2005, 2:e112jmd.amjpathol.org - The Journal of Molecular Diagnostics
